Assembling evidence grade
Loading
Independent evidence before payment.
GHRH analogue · also: GHRH 1-29, GRF 1-29
Sermorelin carries an Evidence Grade of C (Medium confidence). The strongest published evidence catalogued is human (other).
Grade C rule: At least one other human study.
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Human-use stop
This compound is investigational, warned or not approved for human use. A seller calling it “research only,” showing testimonials, registering a company or publishing a COA does not create an approved consumer medicine. Seller links below are market-surveillance records, not recommendations.
Sermorelin is a GHRH analogue historically used as a diagnostic agent for growth-hormone assessment, with a longer clinical track record than most secretagogues here.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there is 1 human study, but no randomised trial — the strongest test has not been done. Effects seen in smaller studies often do not hold up.
Strongest: randomised or pooled human trials.
none catalogued
Observational, open-label or small human studies.
A potentially effective drug for patients with recurrent glioma: sermorelin. Annals of translational medicine, 2021.
Preclinical animal models — not a human outcome.
none catalogued
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.), 2026.
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026.
Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples. Analytical biochemistry, 2023.
Online large volume sample staking preconcentration and separation of enantiomeric GHRH analogs by capillary electrophoresis. Electrophoresis, 2023.
An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. Journal of pharmaceutical and biomedical analysis, 2022.
Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug testing and analysis, 2021.
Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 2020.
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical interventions in aging, 2006.
PEGylation of growth hormone-releasing hormone (GRF) analogues. Advanced drug delivery reviews, 2003.
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999.
Growth hormone-releasing peptides: clinical and basic aspects. Hormone research, 1996.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
Approved historical use is diagnostic. Broader physique or longevity claims are not established by that evidence.
Not an approved medicine in major markets. Sold only as a “research chemical”, with no established safe consumer use, dose or supply standard.
PepCred flags any vendor selling this compound to the public as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Sample of 8 (not ranked) — see all on ClinicalTrials.gov:
No FDA-approved (US) drug labelling found for this compound. A search of openFDA returned no approved product containing it as an active ingredient.
This reflects US FDA approval only — other regulators (e.g. MHRA, EMA) may differ; see the note below. Absence of an approved label is not, by itself, a safety finding, and a “research use only” label does not establish safety, legality or correct identity.
PepCred note: Previously approved as a diagnostic; status varies by jurisdiction.
These unranked records show where the name was detected. For an investigational, warned or unapproved compound, no seller, company registration, review score or COA creates an approved human-use route.
None of these is verified for human use.